Labcorp Holdings Inc. (NYSE:LH) Stock Rated “Moderate Buy” by Wall Street Analysts

Labcorp Holdings Inc. (NYSE:LH) has earned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $337.73.

A number of research analysts recently commented on the stock. Barclays increased their price target on shares of Labcorp from $320.00 to $330.00 and gave the company an “equal weight” rating in a report on Friday, September 11th. UBS Group boosted their price objective on Labcorp from $361.00 to $380.00 and gave the stock a “buy” rating in a research note on Friday, September 11th. Bank of America upped their price objective on Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Piper Sandler lifted their target price on Labcorp from $300.00 to $309.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Finally, Morgan Stanley boosted their target price on Labcorp from $308.00 to $338.00 and gave the company an “overweight” rating in a research report on Friday, July 31st.

Insiders Place Their Bets

In other Labcorp news, Director Kerrii Anderson sold 3,000 shares of Labcorp stock in a transaction on Monday, August 17th. The shares were sold at an average price of $318.02, for a total transaction of $954,060.00. Following the completion of the transaction, the director directly owned 6,563 shares of the company’s stock, valued at $2,087,165.26. The trade was a 31.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Amy Summy sold 924 shares of the business’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total transaction of $283,427.76. Following the transaction, the executive vice president owned 6,956 shares in the company, valued at $2,133,683.44. This trade represents a 11.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 8,593 shares of company stock valued at $2,733,295 over the last three months. 0.84% of the stock is owned by company insiders.

Hedge Funds Weigh In On Labcorp

Several hedge funds have recently added to or reduced their stakes in the company. Victory Capital Management Inc. increased its stake in shares of Labcorp by 103.1% during the fourth quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company’s stock valued at $1,343,922,000 after buying an additional 2,719,475 shares during the period. Boston Partners purchased a new stake in Labcorp in the fourth quarter worth about $480,271,000. Norges Bank purchased a new stake in Labcorp in the fourth quarter worth about $248,006,000. Diamond Hill Capital Management LLC Investment Advisor bought a new position in Labcorp during the 2nd quarter worth about $168,222,000. Finally, Bank of New York Mellon Corp purchased a new position in Labcorp during the 2nd quarter valued at about $142,125,000. 95.94% of the stock is currently owned by institutional investors.

Labcorp Trading Up 0.0%

Shares of LH opened at $311.81 on Thursday. The stock has a market capitalization of $25.29 billion, a PE ratio of 25.79, a P/E/G ratio of 1.78 and a beta of 0.87. The company’s fifty day moving average is $320.19 and its 200 day moving average is $286.74. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80. Labcorp has a fifty-two week low of $244.52 and a fifty-two week high of $341.80.

Labcorp (NYSE:LH) last released its quarterly earnings data on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, beating the consensus estimate of $4.78 by $0.21. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The business had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.71 billion. During the same quarter last year, the business earned $4.35 earnings per share. Labcorp’s quarterly revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Sell-side analysts expect that Labcorp will post 18.32 earnings per share for the current fiscal year.

About Labcorp

Labcorp (NYSE:LH), formally Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing, drug development services and technology-enabled laboratory solutions to healthcare providers, pharmaceutical and biotechnology companies, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including testing related to oncology, women’s health, infectious diseases, genetics and genomics.